Langzeitergebnisse der interventionellen Therapie von großen, inoperablen hepatozellulären Karzinomen (HCC): signifikanter Überlebensvorteil von transarterieller Chemoembolisation (TACE) und perkutaner Ethanolinjektion (PEI) gegenüber der TACE-Monotherapie

Zusammenfassung

Einleitung: Die Effektivität der Kombinationstherapie aus transarterieller Chemoembolisation und perkutaner Ethanolinjektion und der Chemoembolisation-Monotherapie wurde bei Patienten mit großen, nichtresektablen hepatozellulären Karzinomen retrospektiv analysiert. Material und Methode: 50 Patienten mit großen, nicht resezierbaren HCC wurden mit selektiver TACE behandelt. 42 dieser Patienten hatten eine Leberzirrhose aufgrund nutritiv toxischer (n = 22) oder viraler (n = 17) Genese. Bei drei Patienten blieb die Ursache der Leberzirrhose unklar. Im Child-Stadium A befanden sich 22 Patienten, 20 im Stadium Child B. 22 Patienten wurden mit mehrfachen Kombinationstherapien aus TACE und PEI behandelt, 28 erhielten die wiederholte TACE als Monotherapie. Überlebensraten und Behandlungskomplikationen wurden bestimmt und verglichen. Ergebnisse: Die 6-, 12-, 24- und 36-Monats-Überlebensraten (Kaplan und Meier) betrugen für die TACE-Monotherapie 61, 21, 4 und 4 %, für die Kombination aus TACE und PEI 77, 55, 39 und 22 %. Der Einfluss der Therapieform auf die Überlebensrate war im Log-Rank-Test (p = 0,002) signifikant. Ernsthafte Nebenwirkungen traten bei zwei Patienten in der Monotherapiegruppe und bei drei Patienten in der Kombinationstherapiegruppe auf. Schlussfolgerungen: Die Kombination aus TACE und PEI ist eine sichere und effektive, palliative Behandlungsmethode für große hepatozelluläre Karzinome, die das Patientenüberleben im Vergleich zur TACE-Monotherapie verlängern kann.

Abstract

Purpose: A retrospective analysis of long-term efficacy of combined transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) and TACE monotherapy was conducted in patients with large, non-resectable hepatocellular carcinoma (HCC). Methods and Materials: Fifty patients with large, unresectable HCC lesions underwent selective TACE. Liver cirrhosis was present in 42 patients, due to alcohol abuse (n = 22) and viral infection (n = 17). In three patients, the underlying cause for liver cirrhosis remained unclear. Child A cirrhosis was found in 22 and Child B cirrhosis in 20 patients. Repeated and combined TACE and PEI were performed in 22 patients and repeated TACE monotherapy was performed in 28 patients. Survival and complication rates were determined and compared. Results: The 6-,12-, 24- and 36-month survival rates were 61 %, 21 %, 4 %, and 4 % for TACE monotherapy and 77 %, 55 %, 39 % and 22 % for combined TACE and PEI (Kaplan-Meier method). The kind of treatment significantly affected the survival rate (p = 0.002 log-rank test). Severe side effects were present in two patients of the monotherapy group and in three patients of the combination therapy group. Conclusion: The combination of TACE and PEI is an effective and safe method in the palliative treatment of large HCC that has the potential of improving long term survival compared to TACE monotherapy.

Hepatocellular carcinoma (HCC) - combined treatment - transcatheter arterial chemoinfusion - transcatheter arterial chemoembolization (TACE) - percutaneous ethanol injection (PEI)

Literatur

• 1 El-Serag H B. Epidemiology of hepatocellular carcinoma.  Clin Liver Dis. 2001;  5 87-107
• 2 Parkin D M, Bray F I, Devesa S S. Corrigendum to „Cancer burden in the year 2000. The global picture” [European Journal of Cancer 2001; 37 (Suppl. 8): S4-S66].  Eur J Cancer. 2003;  39 848
• 3 Bruix J, Castells A, Bosch J. et al . Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.  Gastroenterology. 1996;  111 1018-1022
• 4 McGhana J P, Dodd G D. III. Radiofrequency ablation of the liver: current status.  Am J Roentgenol. 2001;  176 3-16
• 5 Allgaier H P, Deibert P, Olschewski M. et al . Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection - a single-center analysis including 132 patients.  Int J Cancer. 1998;  79 601-605
• 6 Tanaka K, Nakamura S, Numata K. et al . The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis.  Cancer. 1998;  82 78-85
• 7 Serra M A, Escudero A, Rodriguez F. et al . Effect of hepatitis C virus infection and abstinence from alcohol on survival in patients with alcoholic cirrhosis.  J Clin Gastroenterol. 2003;  36 100-102
• 8 Huppert P E, Lauchart W, Duda S H. et al . Chemoembolisation des hepatozellulären Karzinoms: welche Faktoren bestimmen Therapieansprechen und Überleben?.  Fortschr Röntgenstr. 2004;  176 375-385
• 9 Nakamura H, Hashimoto T, Oi H. et al . Transcatheter oily chemoembolization of hepatocellular carcinoma.  Radiology. 1989;  170 783-786
• 10 Hatanaka Y, Yamashita Y, Takahashi M. et al . Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management.  Radiology. 1995;  195 747-752
• 11 Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases.  Cancer. 1994;  73 2259-2267
• 12 Matsui O, Kadoya M, Kameyama T. et al . Benign and malignant nodules in cirrhotic livers: distinction based on blood supply.  Radiology. 1991;  178 493-497
• 13 Konno T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium.  Cancer. 1990;  66 1897-1903
• 14 Egawa H, Maki A, Mori K. et al . Effects of intra-arterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in lipiodol on experimental liver tumor in rats.  J Surg Oncol. 1990;  44 109-114
• 15 Caturelli E, Siena D A, Fusilli S. et al . Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study.  Radiology. 2000;  215 123-128
• 16 Yamada R, Sato M, Kawabata M. et al . Hepatic artery embolization in 120 patients with unresectable hepatoma.  Radiology. 1983;  148 397-401
• 17 Kan Z, Sato M, Ivancev K. et al . Distribution and effect of iodized poppyseed oil in the liver after hepatic artery embolization: experimental study in several animal species.  Radiology. 1993;  186 861-866
• 18 Llovet J M, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.  Hepatology. 2003;  37 429-442
• 19 Lo C M, Ngan H, Tso W K. et al . Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.  Hepatology. 2002;  35 1164-1171
• 20 Camma C, Schepis F, Orlando A. et al . Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.  Radiology. 2002;  224 47-54
• 21 Lu C D, Qi Y G, Peng S Y. Lipiodolization with or without gelatin sponge in hepatic arterial chemoembolization for hepatocellular carcinoma.  Chin Med J. 1994;  107 209-215
• 22 Kawai S, Okamura J, Ogawa M. et al . Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma - a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.  Cancer Chemother Pharmacol. 1992;  31 (Suppl) S1-S6
• 23 Shiina S, Tagawa K, Unuma T. et al . Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study.  Cancer. 1991;  68 1524-1530
• 24 Clark T W, Soulen M C. Chemical ablation of hepatocellular carcinoma.  J Vasc Interv Radiol. 2002;  13 S245-S252
• 25 Ishii H, Okada S, Nose H. et al . Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection.  Cancer. 1996;  77 1792-1796
• 26 Livraghi T, Lazzaroni S, Pellicano S. et al . Percutaneous ethanol injection of hepatic tumors: single-session therapy with general anesthesia.  Am J Roentgenol. 1993;  161 1065-1069
• 27 Giorgio A, Tarantino L, De Stefano G. et al . Ultrasound-guided percutaneous ethanol injection under general anesthesia for the treatment of hepatocellular carcinoma on cirrhosis: long-term results in 268 patients.  Eur J Ultrasound. 2000;  12 145-154
• 28 Meloni F, Lazzaroni S, Livraghi T. Percutaneous ethanol injection: single session treatment.  Eur J Ultrasound. 2001;  13 107-115
• 29 Daniele B, De Sio I, Izzo F. et al . Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: a Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study.  J Clin Gastroenterol. 2003;  36 63-67
• 30 Yamamoto J, Okada S, Shimada K. et al . Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection.  Hepatology. 2001;  34 707-713
• 31 Lencioni R, Vignali C, Caramella D. et al . Transcatheter arterial embolization followed by percutaneous ethanol injection in the treatment of hepatocellular carcinoma.  Cardiovasc Intervent Radiol. 1994;  17 70-75
• 32 Dimitrakopoulou-Strauss A, Strauss L G, Gutzler F. et al . Pharmacokinetic imaging of 11C ethanol with PET in eight patients with hepatocellular carcinomas who were scheduled for treatment with percutaneous ethanol injection.  Radiology. 1999;  211 681-686
• 33 Tanaka K, Nakamura S, Numata K. et al . Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization.  Radiology. 1992;  185 457-460
• 34 Koda M, Murawaki Y, Mitsuda A. et al . Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study.  Cancer. 2001;  92 1516-1524
• 35 Bartolozzi C, Lencioni R, Caramella D. et al . Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization.  Radiology. 1995;  197 812-818
• 36 Bruix J, Sherman M, Llovet J M. et al . Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.  J Hepatol. 2001;  35 421-430
• 37 Vogl T J, Eichler K, Zangos S. et al . Das hepatozelluläre Karzinom. Rolle der Bildgebung zur Detektion, Therapieplanung und Therapiekontrolle.  Fortschr Röntgenstr. 2002;  174 1358-1368